Pai Life Sciences, Inc.
Publicly observedSeattle, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Seattle | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Pai Life Sciences, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MSMLUCM9DRT6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant21 Sept 2026Publicly observed
NIH SBIR/STTR award: LiT4Q TLR4 Agonist Formulation for Mucosal Melanoma
USD 391,300.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Mar 2019Publicly observed
NIH SBIR/STTR award: A Vaccine for Lymphatic Filariasis, LFGuard™
USD 713,883.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Mar 2019Publicly observed
NIH SBIR/STTR award: A Vaccine for Lymphatic Filariasis, LFGuard™
USD 452,996.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.